ASCIA Submissions and Reports

ASCIA Submissions 2020-2023 | ASCIA Submissions 2019 | ASCIA Annual Highlights, Annual Reports, AGM Minutes, Financial Reports | ASCIA Scope of Practice documentsNational Allergy Strategy  | ASCIA/NPS Choosing Wisely Australia and RACP Evolve recommendations  | Allergy in Australia 2014 | Allergy and Immune Diseases in Australia (AIDA) Report 2013 | ASCIA Education Resources Report 2013 | Economic Impact of Allergies Report 2007

ASCIA continues to advocate on behalf of ASCIA members to government and other organisations by lodging submissions which are listed below. 

ASCIA Submissions 2023

  • ASCIA has lodged two submissions on 23 May 2023 in support of products that are relevant to allergy and immunology, which are on the July 2023 PBAC meeting agenda.

pdfASCIA letter PBAC Avacopan 2023 05 2366.18 KB

 pdfASCIA letter PBAC Dupilumab 2023 05 23 67.24 KB

  • ASCIA letter to the Australian Government Department of Health, to provide information to address the Medical Treatment Overseas Program (MTOP) eligibility criteria for thymic transplant, submitted in May 2023.
  • ASCIA has submitted two letters in support of applications for  Medical Research Future Fund (MRFF) research grants, in February and May 2023.
  • ASCIA has submitted two joint letters to the federal Health Minister, the Hon Mark Butler MP, with the National Allergy Council and Allergy & Anaphylaxis Australia regarding the feasibility of pricing for PBS listed products -  venom immunotherapy (May 2023) and medical nutrition products for cow’s milk allergy (April 2023).

ASCIA Submissions 2022

  • ASCIA letter to Medical Services Advisory Committee (MSAC) in support for the Human Genetics Society of Australasia (HGSA) application for services provided by genetic counsellors, submitted on 7 October 2022.
    pdfASCIA supports HGSA MSAC application 20221007
  • ASCIA letter to PBAC supporting the PBS listing of PBS Nucala® (mepolizumab) for treatment of nasal polyps in chronic rhinosinusitis, submitted on 20 September 2022.
    pdfASCIA letter PBAC Nucala 2022092069.78 KB Nucala® (mepolizumab) is now subsidised by the Pharmaceutical Benefits Scheme (PBS) from 1 April 2023 as an add-on treatment for adult patients (18 years and above) with chronic rhinosinusitis with nasal polyps (CRSwNP) that is severe, eosinophilic and recurrent post-surgery.. Read more here
  • Joint letter to the federal Health Minister, the Hon Mark Butler MP, regarding pricing of medical nutrition products for cow’s milk allergy has been sent on behalf of ASCIA, Allergy & Anaphylaxis Australia and the National Allergy Strategy, submitted on 28 July 2022.
  • Letters from ASCIA supporting research project appications to the Medical Research Future Fund (MRFF) have been submitted on 16 February, 3 March, 16 May, 24 June and 1 July 2022.
  • ASCIA letter to the Australian Government Department of Health, to provide information to address the Medical Treatment Overseas Program (MTOP) eligibility criteria about a SCID-ADA patient, in response to a request sent to ASCIA on 8 July 2022. Lodged 20 July 2022. 
  • ASCIA submitted responses to a survey on the Consultation Draft - National Medicines Policy. Lodged 2 March 2022. 
  • Letter from ASCIA in support of the application to the PBAC for PBS listing of Dupixent® (dupilumab) for treatment of severe atopic dermatitis (eczema) in children aged 6-11 years. Lodged 13 January 2022.
    pdfASCIA letter PBAC Dupilumab 2022 01 1352.73 KB
  • ASCIA letter to the Australian Government Department of Health, to provide information to address the Medical Treatment Overseas Program (MTOP) eligibility criteria about a patient with DiGeorge Syndrome and Severe Combined Immune Deficiency (SCID), in response to a request sent to ASCIA on 4 January 2022. Lodged 12 January 2022. 

ASCIA Submissions 2021

  • ASCIA response to National Blood Authority (NBA) call for public comments on the draft Acute Transfusion Reaction Guidelines. Lodged online 2 July 2021.

ASCIA Submissions 2020

  • ASCIA Immunodeficiency Strategy for Australia and New Zealand. Completed November 2020 and lodged as an attached to the ASCIA submission to the Parliamentary Inquiry 3 November 2020.

  • Joint letter from ASCIA, National Allergy Strategy, A&AA and CFAR to the Minister for Health (Hon Greg Hunt MP), in response to Recommendation 1 in the Report on the Parliamentay Inquiry into Allergies and Anaphylaxis. Submitted 30 June 2020. pdfJoint letter to Minister Hunt 30-06-20100.27 KB

ASCIA Submissions 2019

ASCIA Annual Highlights, Annual Reports, AGM Minutes, Financial Reports

Summaries of annual highlights

ASCIA Annual General Meeting (AGM) Minutes

ASCIA Annual Reports

ASCIA Financial Reports are available on the Australian Charities and Not-for-profits Commission (ACNC) website (ASCIA is a Company limited by guarantee (ACN 608 798 241; ABN 45 615 521 452) and is registered with the ACNC.

ASCIA Scope of Practice documents

Scope of Practice - Allergy Skin Testing in Australia 2018

ASCIA developed this Scope of Practice  in response to the Medicare Benefits Schedule (MBS) item number changes implemented by the MBS Review Taskforce, effective 1 November 2018.  Whilst these changes were not initiated by ASCIA, the previously proposed item numbers were significantly modified in response to a submission made by ASCIA in July 2017, to ensure patients with complex allergic disease are not disadvantaged.

pdfASCIA Scope of Practice - Allergy Skin Testing in Australia 2018171.23 KB

Scope of Practice - Specialist Physicians in Immunology and Allergy in  Australia 2014

The aim of this Scope of Practice is to outline the range of practice of clinical immunology/allergy specialists in Australia and ensure that patients with allergic and other immune diseases receive the highest standard of care, in line with best clinical practice. 

pdfASCIA Scope of Practice Australia July 2014208.16 KB 

National Allergy Strategy

In 2021 ASCIA continues to contribute to, and promote the following National Allergy Strategy projects:

ASCIA Recommendations - NPS Choosing Wisely Australia and RACP Evolve 

choosing wiselyASCIA was the first Specialty Society affiliated with the Royal Australasian College of Physicians (RACP) to be involved in Choosing Wisely Australia, a health profession led initiative faciliated by National Prescribing Service (PBS) MedicineWise and the RACP Evolve program.  The ASCIA list of five things that clinicians and consumers should question is available at:

For further information about Choosing Wisely Australia go to  

 For further information about the RACP Evolve program go to

Allergy in Australia 2014

ASCIA Allergy in Australia 2014 Prior to ASCIA developing a National Allergy Strategy for Australia, the following report was developed in 2014. 

pdfAllergy in Australia 2014: A submission for allergic diseases to be recognised as a National Health Priority Area 606.54 KB

Allergy and Immune Diseases in Australia (AIDA) Report 2013

ascia aida report 2013The AIDA report on allergy and other immune diseases (immunodeficiency and autoimmune diseases) was developed in 2013.

pdfAllergy and Immune Diseases in Australia (AIDA) Report 2013720.33 KB  


ASCIA Education Resources Report 2013

ASCIA Education Resources ReportASCIA has been developing web based education resources since 1999. In 2013, the ASCIA Education Resouces Report was developed to outline the large range of web based educational resources that are all available at no charge on the ASCIA website.

pdfASCIA_Education_Report_July_2013483.57 KB   


Economic Impact of Allergies Report 2007

Economic Impact of AllergiesThe cost of allergies to the Australian economy is estimated to be $7.8 billion, with lost productivity and health system expenditure the major contributing factors. Furthermore, most Australians with allergies face a wait many months to see a specialist, if they can access care at all. These are among key findings in the following report 'Economic Impact of Allergies' by Access Economics that was released by ASCIA in November 2007. 

pdfEconomic Impact of Allergies Report - 20071.65 MB 

Content updated May 2023

Mod ASCIA Member
Donate to AIFA
go to NAC website

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links


ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Information Partner

Official Information Partner of Healthdirect Australia